臨床泌尿器科69巻1号

2015年01月発行

特集 LOH症候群診療—最近の進歩

ホルモン補充療法（注射製剤）の有用性—健康関連QOLに着目して

著者： 小中弘之¹ 並木幹夫¹

所属機関： ¹金沢大学大学院医学系研究科集学的治療分野（泌尿器科学）

ページ範囲：P.60 - P.67

要旨　Late-onset hypogonadism（LOH）症候群の診療理念は，中高年男性の健康促進とQOLの改善にある。最近ようやく，その治療手段であるホルモン補充療法の有用性がいくつかの臨床試験によって検証され，そのエビデンスの蓄積は着実に進んでいる。LOH症候群がQOL疾患である以上，患者の健康状態を直接反映する健康関連QOLは，ホルモン補充療法の介入試験において極めて重要なエンドポイントとなりうる。本稿では治療介入を伴うLOH症候群における健康関連QOL評価の重要性を強調しつつ，本邦で施行されたEARTH試験の概要と結果についても言及し，ホルモン補充療法（注射製剤）による健康関連QOLの改善を報告する。

参考文献

1）Patrick DL, Burke LB, Powers JH, et al：Patient-reported outcomes to support medical product labeling claims：FDA perspective. Value Health 10 Suppl 2：S125-137, 2007

2）Heinemann GD, Schmitt MH, Farrell MP, et al：Development of an attitudes toward health care teams scale. Eval Health Prof 22：123-142, 1999

3）Morley JE, Charlton E, Patrick P, et al：Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49：1239-1242, 2000

4）Bhasin S, Cunningham GR, Hayes FJ, et al：Testosterone therapy in men with androgen deficiency syndromes：an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95：2536-2559, 2010

5）Lunenfeld B, Saad F and Hoesl CE：ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males：scientific background and rationale. Aging Male 8：59-74, 2005

6）T'Sjoen G, Goemaere S, De Meyere M, et al：Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 29：201-214, 2004

7）McMillan CV, Bradley C, Giannoulis M, et al：Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline：the A-RHDQoL. Health Qual Life Outcomes 1：51, 2003

8）Ware JE Jr and Sherbourne CD：The MOS 36-item short-form health survey（SF-36）. I. Conceptual framework and item selection. Med Care 30：473-483, 1992

9）Bergner M, Bobbitt RA, Carter WB, et al：The Sickness Impact Profile：development and final revision of a health status measure. Med Care 19：787-805, 1981

10）Endicott J, Nee J, Harrison W, et al：Quality of life enjoyment and satisfaction questionnaire：a new measure. Psychopharmacol Bull 29：321-326, 1993

11）Langham S, Maggi M, Schulman C, et al：Health-related quality of life instruments in studies of adult men with testosterone deficiency syndrome：a critical assessment. J Sex Med 5：2842-2852, 2008

12）Haren MT, Wittert GA, Chapman IM, et al：Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 50：124-133, 2005

13）Fugl-Meyer AR, Lodnert G, Branholm IB, et al：On life satisfaction in male erectile dysfunction. Int J Impot Res 9：141-148, 1997

14）Ware J Jr, Kosinski M and Keller SD：A 12-item short-form health survey：construction of scales and preliminary tests of reliability and validity. Med Care 34：220-233, 1996

15）Bhasin S, Storer TW, Asbel-Sethi N, et al：Effects of testosterone replacement with a nongenital, transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83：3155-3162, 1998

16）Snyder PJ, Peachey H, Hannoush P, et al：Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84：2647-2653, 1999

17）English KM, Steeds RP, Jones TH, et al：Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina：a randomized, double-blind, placebo-controlled study. Circulation 102：1906-1911, 2000

18）Rabkin JG, Wagner GJ and Rabkin R：A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 57：141-147；discussion 155-146, 2000

19）Reddy P, White CM, Dunn AB, et al：The effect of testosterone on health-related quality of life in elderly males-a pilot study. J Clin Pharm Ther 25：421-426, 2000

20）Seidman SN, Spatz E, Rizzo C, et al：Testosterone replacement therapy for hypogonadal men with major depressive disorder：a randomized, placebo-controlled clinical trial. J Clin Psychiatry 62：406-412, 2001

21）Ly LP, Jimenez M, Zhuang TN, et al：A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86：4078-4088, 2001

22）Kenny AM, Bellantonio S, Gruman CA, et al：Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57：M321-325, 2002

23）Leder BZ, Rohrer JL, Rubin SD, et al：Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 89：1174-1180, 2004

24）Shabsigh R, Kaufman JM, Steidle C, et al：Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172：658-663, 2004

25）Haren M, Chapman I, Coates P, et al：Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 34：125-130, 2005

26）Katznelson L, Robinson MW, Coyle CL, et al：Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. Eur J Endocrinol 155：867-875, 2006

27）Merza Z, Blumsohn A, Mah PM, et al：Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 29：381-391, 2006

28）Okun MS, Fernandez HH, Rodriguez RL, et al：Testosterone therapy in men with Parkinson disease：results of the TEST-PD Study. Arch Neurol 63：729-735, 2006

29）Emmelot-Vonk MH, Verhaar HJ, et al：Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men：a randomized controlled trial. JAMA 299：39-52, 2008

30）Knapp PE, Storer TW, Herbst KL, et al：Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 294：E1135-1143, 2008

31）Legros JJ, Meuleman EJ, Elbers JM, et al：Oral testosterone replacement in symptomatic late-onset hypogonadism：effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 160：821-381, 2009

32）Aversa A, Bruzziches R, Francomano D, et al：Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome：results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 7：3495-3503, 2010

33）Giltay EJ, Tishova YA, Mskhalaya GJ, et al：Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 7：2572-2582, 2010

34）Behre HM, Tammela TL, Arver S, et al：A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 15：198-207, 2012

35）Ho CC, Tong SF, Low WY, et al：A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 110：260-265, 2012

36）Tong SF, Ng CJ, Lee BC, et al：Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome：a double blind randomized controlled trial. Asian J Androl 14：604-611, 2012